Gensight Biologics SA banner

Gensight Biologics SA
PAR:SIGHT

Watchlist Manager
Gensight Biologics SA Logo
Gensight Biologics SA
PAR:SIGHT
Watchlist
Price: 0.0888 EUR 3.86% Market Closed
Market Cap: €19.6m

Wall Street
Price Targets

SIGHT Price Targets Summary
Gensight Biologics SA

Wall Street analysts forecast SIGHT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SIGHT is 0.4386 EUR with a low forecast of 0.404 EUR and a high forecast of 0.483 EUR.

Lowest
Price Target
0.404 EUR
355% Upside
Average
Price Target
0.4386 EUR
394% Upside
Highest
Price Target
0.483 EUR
444% Upside
Gensight Biologics SA Competitors:
Price Targets
MASI
Masimo Corp
1% Upside
LAND
Gladstone Land Corp
2% Upside
RLMD
Relmada Therapeutics Inc
38% Upside
ESQ
Esquire Financial Holdings Inc
15% Upside
VINP
Vinci Partners Investments Ltd
36% Upside
AMAL
Amalgamated Bank
7% Upside

Revenue
Forecast

N/A
Past Growth
174% / Year
Estimated Growth
Estimates Accuracy
-55%
Average Miss
N/A
Past Growth
174% / Year
Estimated Growth
Estimates Accuracy
-55%
Average Miss

The compound annual growth rate of Gensight Biologics SA's revenue for the next 3 years is 174%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-85%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-85%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is SIGHT's stock price target?
Price Target
0.4386 EUR

According to Wall Street analysts, the average 1-year price target for SIGHT is 0.4386 EUR with a low forecast of 0.404 EUR and a high forecast of 0.483 EUR.

What is Gensight Biologics SA's Revenue forecast?
Projected CAGR
174%

The compound annual growth rate of Gensight Biologics SA's revenue for the next 3 years is 174%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett